EQL Pharma to exclusively launch first CE marked saliva based Covid-19 antigen self-test

EQL Pharma will soon complement its current “nasal swab” Covid-19 antigen test with a saliva-based CE marked self-test for quick detection of a Covid-19 infection. “You basically spit in a cup rather that swab the nasal cavity with a tops” says the vice president Axel Schörling, “then the saliva is mixed with a reagent and dripped on a reagent stick which will show if there is virus present in about 5-15 minutes”.

The test is the first CE marked of its kind that can be sold and used by normal consumers rather than healthcare professionals, and EQL has an exclusivity for it on the Nordic market. “We are very proud to be the first company in the Nordics able to offer a more comfortable way of testing yourself and your loved ones for an ongoing Covid-19 infection, without having to first seek the help of a healthcare professional” Axel Schörling concludes.

EQL’s saliva test will become available in Sweden at the middle of October and EQL have plans to introduce it in the other Nordic countries during the autumn.

For further information, please contact:
Axel Schörling
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 763 – 17 90 60
E-mail: axel.schorling@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.